Clinical Trial Update: A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating CAR T cells targeting CD19 for malignant B-cell leukemia and lymphoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• CAR-γδT cells targeting CD19 (CAR-γδT cell therapy encoding anti-CD19 specificity)

Snippet

Sponsor: Southwest Hospital, China | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN